周一盘中，巨子生物（02367.HK）股价大涨5.15%，引发市场关注。这波涨势很可能源于公司近期发布的2024年度亮眼业绩报告。
根据巨子生物发布的2024年年度业绩，公司表现出色。2024年公司收入达55.4亿元，同比增长57%；净利润20.6亿元，同比增长42%，净利率维持在37.2%的高水平。公司两大核心品牌表现突出，可复美品牌收入达45.4亿元，同比增长62.9%，可丽金品牌收入8.4亿元，同比增长36.3%。此外，公司线上直销收入同比增长70%，显示出强劲的增长势头。
巨子生物还宣布了可观的派息计划，拟派息12.4亿元，其中包括每股0.602元的末期股息和每股0.592元的特别股息。公司在研发方面的投入也不断加大，2024年研发支出1.1亿元，同比增长42.1%，目前拥有188项在研项目和167项专利。这些因素综合起来，显示出公司强劲的业绩表现和良好的发展前景，很可能是推动股价上涨的主要原因。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.